# Mesa Laboratories share price today (Mesa Laboratories, Inc., MLAB)

> Mesa Laboratories, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 23% of past readings. MLAB · Technology · Scientific & Technical Instruments · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/mlab

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $125.48 (+74.5% in a year)
- P/E: 145.8× (lower than 77% of the last 4.6 years)
- Revenue (Jun 2026): $60.1 M (+1.0% on a year ago)
- Profit (Jun 2026): $2.8 M (−40.3% on a year ago)
- Operating margin: 11.7% (+6.6 points on a year ago)
- ROE: 4%, FY26
- ROIC: 3.6%, against a 8.9% cost of capital: −5.3 points
- Profit that came in as cash: 1,157%, last 3 years

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the Mesa Laboratories share price today? Mesa Laboratories, Inc.'s share price was $125.48 at the close on 3 November 2026. It has been rising for 15 weeks. That is 20.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $71 and $134, and at that close it sat 87% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 10 years the share price moved +0% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Mesa Laboratories pay? Mesa Laboratories, Inc. paid $0.64 per share over the last four reported quarters. The most recent declaration was $0.16 for Jun 2026. At today's price of $125.48 that is a yield of 0.51%, based on dividends already paid, not a forecast. ## Which stock lists is Mesa Laboratories on? Mesa Laboratories is on one of our US lists: US tech stocks. [US tech stocks](https://www.sectoralpha.in/us-tech-stocks)

## Is Mesa Laboratories profitable? Mesa Laboratories, Inc. earned $2.8 M of net profit in the Jun 2026 quarter, −40.3% on the same quarter a year earlier. Full-year FY26 profit was $6.7 M. Over 4 years profit has grown 37.6% a year on average. That is 4.7% of the quarter's revenue. The same quarter a year earlier earned $4.7 M. 5 of the last 12 reported quarters were loss-making. ## How much revenue does Mesa Laboratories make, and is it growing? Mesa Laboratories, Inc. reported $60.1 M of revenue in the Jun 2026 quarter, +1.0% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 4 years it has grown 7.8% a year on average. The last full year, FY26, came in at $249 M. The last four reported quarters add to $250 M. FY26 revenue was $249 M, +3.4% on the year before. Recent pace: the last four quarters grew +3.0% on average, against 7.8% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +3.0%, against +5.7% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Mesa Laboratories keep? Mesa Laboratories, Inc.'s operating margin was 11.7% in the Jun 2026 quarter, 6.6 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 1.5% and 7.4%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +6.6 percentage points on the year while gross margin changed +2.9 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead. ## Is Mesa Laboratories' profit turning into cash? Over the last 3 years, 1,157% of Mesa Laboratories, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in $42.8 M of operating cash against $6.7 M of profit. After $3.3 M of spending on assets, $39.6 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Mesa Laboratories' cash go? Mesa Laboratories, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $10.1 M on assets over the last 3 years. Averaged over those years that is 1.3% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $10.1 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Mesa Laboratories' P/E ratio, and how does it compare with its own history? Mesa Laboratories, Inc.'s P/E is 145.8×, near the low end of its own history: it has been lower only 23% of the time. Its usual P/E (the middle reading) is 419.3×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks. Where the price move came from: over 3 years the price moved +10.4% a year; about +37.1% a year came from earnings growth and about −26.7 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Mesa Laboratories business getting better or worse? Mesa Laboratories, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Mesa Laboratories earn on its capital? Mesa Laboratories, Inc. earned a ROE of 4% in FY26. That is up from a low of −175% in FY24. Its return on capital used (ROIC) is 5.3 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 2.7% net margin and 0.58× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 2.7% net margin × 0.58× asset turnover × 2.30× leverage (assets divided by equity) ≈ 3.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 3.6% − 8.9% = −5.3 percentage points. The 8.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Mesa Laboratories have too much debt? Mesa Laboratories, Inc. has total debt of $161 M against shareholder equity of $189 M as of Jun 2026, so its debt is 0.85× its equity. Year by year, that ratio went from 0.58 in FY22 to 0.91 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Mesa Laboratories shareholding pattern? 7.9% of Mesa Laboratories, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Mesa Laboratories from balance-sheet trouble? For Mesa Laboratories, Inc., the Z-score is 1.49. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.49 is inside the danger zone, so the balance sheet is a real risk. ## How does Mesa Laboratories rank in its industry? 46.8 out of 100, rank 13 of 19 in Scientific & Technical Instruments, with 74% of the evidence available. Mesa Laboratories, Inc. scores 46.8 out of 100 against the 19 companies it is compared with in Scientific & Technical Instruments, ranking 13. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.8 + 6 + 3.9 + 19.1 = 46.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Mesa Laboratories compared with? Mesa Laboratories ranks 13 of 19 Scientific & Technical Instruments companies on the 4-Factor Sector Score, with 46.8 out of 100. 1. [Garmin Ltd.](https://www.sectoralpha.in/us/stocks/grmn) GRMN · losing its lead · Most evidence points up · 81% evidence 69.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.1/35 · Revenue 13.5% · Profit 19.7% · Operating margin change 4.4 points · 83% evidence Capital efficiency 21.0/25 · ROCE 22.7% · Operating margin 30.4% · 76% evidence Valuation 12.0/20 · P/E 23.9× · PEG 1.22 · 65% evidence Relative strength 14.5/20 · Lead over its industry 6.5% · Lead over S&P 500 6.3% · 1 year 34.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.1 + 21 + 12 + 14.5 = 69.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Keysight Technologies, Inc.](https://www.sectoralpha.in/us/stocks/keys) KEYS · losing its lead · Most evidence points up · 85% evidence 65.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.1/35 · Revenue 25.5% · Profit 100% · Operating margin change 7.6 points · 95% evidence Capital efficiency 16.3/25 · ROCE 13.7% · Operating margin 25.7% · 76% evidence Valuation 10.1/20 · P/E 43.4× · PEG 1.34 · 65% evidence Relative strength 8.0/20 · Lead over its industry 0.3% · Lead over S&P 500 -0.4% · 1 year 68.7% · 100% evidence · 2 of 12 weeks ahead Exact sum: 31.1 + 16.3 + 10.1 + 8 = 65.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Teledyne Technologies Incorporated](https://www.sectoralpha.in/us/stocks/tdy) TDY · quiet · Evidence leans up · 85% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.8/35 · Revenue 8.6% · Profit 25.5% · Operating margin change 2.3 points · 95% evidence Capital efficiency 13.6/25 · ROCE 9.4% · Operating margin 20.8% · 76% evidence Valuation 13.7/20 · P/E 27.7× · PEG 1.04 · 65% evidence Relative strength 16.0/20 · Lead over its industry 3.5% · Lead over S&P 500 3.4% · 1 year 29.3% · 100% evidence · 0 of 12 weeks ahead Exact sum: 20.8 + 13.6 + 13.7 + 16 = 64.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ituran Location and Control Ltd.](https://www.sectoralpha.in/us/stocks/itrn) ITRN · turning · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 15.9% · Profit 14.3% · Operating margin change 1.6 points · 83% evidence Capital efficiency 21.0/25 · ROCE 30% · Operating margin 22.7% · 76% evidence Valuation 12.7/20 · P/E 18.8× · PEG 1.2 · 65% evidence Relative strength 9.0/20 · Lead over its industry -1.5% · Lead over S&P 500 -1.9% · 1 year 37.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 21 + 21 + 12.7 + 9 = 63.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Cognex Corporation](https://www.sectoralpha.in/us/stocks/cgnx) CGNX · quiet · Too little evidence to rank firmly · 58% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.2/35 · Revenue n/a · Profit n/a · Operating margin change 8.5 points · 45% evidence Capital efficiency 16.4/25 · ROCE 12.1% · Operating margin 29.4% · 76% evidence Valuation 9.4/20 · P/E 64.6× · PEG n/a · 15% evidence Relative strength 12.1/20 · Lead over its industry 3.4% · Lead over S&P 500 2.6% · 1 year 48% · 100% evidence · 0 of 12 weeks ahead Exact sum: 24.2 + 16.4 + 9.4 + 12.1 = 62.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. [Vontier Corporation](https://www.sectoralpha.in/us/stocks/vnt) VNT · breaking out · Too little evidence to rank firmly · 58% evidence 59.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.9/35 · Revenue n/a · Profit n/a · Operating margin change 0.5 points · 45% evidence Capital efficiency 18.3/25 · ROCE 19.3% · Operating margin 19.4% · 76% evidence Valuation 11.3/20 · P/E 11.6× · PEG n/a · 15% evidence Relative strength 13.4/20 · Lead over its industry 0.4% · Lead over S&P 500 0.8% · 1 year -3.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 16.9 + 18.3 + 11.3 + 13.4 = 59.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Fortive Corporation](https://www.sectoralpha.in/us/stocks/ftv) FTV · turning · Too little evidence to rank firmly · 58% evidence 58.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.0/35 · Revenue n/a · Profit n/a · Operating margin change 3.6 points · 45% evidence Capital efficiency 11.2/25 · ROCE 7.6% · Operating margin 19.1% · 76% evidence Valuation 9.9/20 · P/E 35.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 9.7% · Lead over S&P 500 9.7% · 1 year 30.4% · 100% evidence · 2 of 12 weeks ahead Exact sum: 19 + 11.2 + 9.9 + 18.3 = 58.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. [MKS Inc.](https://www.sectoralpha.in/us/stocks/mksi) MKSI · quiet · Evidence leans up · 81% evidence 53.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.2/35 · Revenue 16.3% · Profit 64.8% · Operating margin change 6.2 points · 83% evidence Capital efficiency 13.6/25 · ROCE 11% · Operating margin 20.6% · 76% evidence Valuation 11.5/20 · P/E 68.3× · PEG 1.16 · 65% evidence Relative strength 0.8/20 · Lead over its industry -22.1% · Lead over S&P 500 -22.9% · 1 year 32.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.2 + 13.6 + 11.5 + 0.8 = 53.1 · What this means: Earnings are strong; relative strength in its sector is -22.1% and the one-year return is 32.5%. 9. [Trimble Inc.](https://www.sectoralpha.in/us/stocks/trmb) TRMB · breaking out · Too little evidence to rank firmly · 58% evidence 48.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue n/a · Profit n/a · Operating margin change 0 points · 45% evidence Capital efficiency 11.7/25 · ROCE 9.5% · Operating margin 15.1% · 76% evidence Valuation 10.1/20 · P/E 33.4× · PEG n/a · 15% evidence Relative strength 8.8/20 · Lead over its industry -4.2% · Lead over S&P 500 -3.4% · 1 year -16.8% · 100% evidence · 11 of 12 weeks ahead Exact sum: 18.1 + 11.7 + 10.1 + 8.8 = 48.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 10. [ESCO Technologies Inc.](https://www.sectoralpha.in/us/stocks/ese) ESE · quiet · Evidence leans down · 81% evidence 47.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 26.9% · Profit 100% · Operating margin change 0.2 points · 83% evidence Capital efficiency 13.2/25 · ROCE 10.8% · Operating margin 14.8% · 76% evidence Valuation 5.3/20 · P/E 28.8× · PEG 3.45 · 65% evidence Relative strength 3.1/20 · Lead over its industry -11.1% · Lead over S&P 500 -11.6% · 1 year 15.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 13.2 + 5.3 + 3.1 = 47.4 · What this means: Earnings are strong; relative strength in its sector is -11.1% and the one-year return is 15.9%. 11. [Itron, Inc.](https://www.sectoralpha.in/us/stocks/itri) ITRI · quiet · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
12. [Badger Meter, Inc.](https://www.sectoralpha.in/us/stocks/bmi) BMI · turning · Evidence leans down · 85% evidence 46.8 out of 100 Growth Capital Valuation Relative
13. Mesa Laboratories, Inc. this page MLAB · leader · Evidence leans down · 74% evidence 46.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.8/35 · Revenue 2.9% · Profit n/a · Operating margin change 6.6 points · 62% evidence Capital efficiency 6.0/25 · ROCE 6.2% · Operating margin 11.7% · 76% evidence Valuation 3.9/20 · P/E 114.6× · PEG 3.14 · 65% evidence Relative strength 19.1/20 · Lead over its industry 20.8% · Lead over S&P 500 20.5% · 1 year 65.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.8 + 6 + 3.9 + 19.1 = 46.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 14. [Sensata Technologies Holding plc](https://www.sectoralpha.in/us/stocks/st) ST · quiet · Evidence leans down · 81% evidence 45.2 out of 100 Growth Capital Valuation Relative
15. [Novanta Inc.](https://www.sectoralpha.in/us/stocks/novt) NOVT · quiet · Too little evidence to rank firmly · 58% evidence 43.4 out of 100 Growth Capital Valuation Relative
16. [Coherent Corp.](https://www.sectoralpha.in/us/stocks/cohr) COHR · quiet · Most evidence points down · 64% evidence 34.9 out of 100 Growth Capital Valuation Relative
17. [Vishay Precision Group, Inc.](https://www.sectoralpha.in/us/stocks/vpg) VPG · quiet · Too little evidence to rank firmly · 58% evidence 28.5 out of 100 Growth Capital Valuation Relative
18. USBC, Inc. USBC · breaking out · Too little evidence to rank firmly · 40% evidence 41.3 out of 100 Growth Capital Valuation Relative
19. MicroVision, Inc. MVIS · Too little evidence to rank firmly · 37% evidence 34.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Scientific & Technical Instruments](https://www.sectoralpha.in/us/sectors/scientific-technical-instruments), all 19 compared on one page. ## Which companies are close to Mesa Laboratories in size? Mesa Laboratories is the 17th largest of 17 Scientific & Technical Instruments companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Novanta Inc., Vontier Corporation, Badger Meter, Inc., Itron, Inc., Ituran Location and Control and Vishay Precision Group, Inc. It is the smallest. ### Scientific & Technical Instruments companies close in size

1. [Novanta Inc.](https://www.sectoralpha.in/us/stocks/novt) $5.6 billion
2. [Vontier Corporation](https://www.sectoralpha.in/us/stocks/vnt) $4.9 billion
3. [Badger Meter, Inc.](https://www.sectoralpha.in/us/stocks/bmi) $4.4 billion
4. [Itron, Inc.](https://www.sectoralpha.in/us/stocks/itri) $4.3 billion
5. [Ituran Location and Control Ltd.](https://www.sectoralpha.in/us/stocks/itrn) $1 billion
6. [Vishay Precision Group, Inc.](https://www.sectoralpha.in/us/stocks/vpg) $723 million
7. Mesa Laboratories, Inc. $702 million

[All 17 Scientific & Technical Instruments companies, largest first](https://www.sectoralpha.in/us/sectors/scientific-technical-instruments#all-companies)

### Companies close in size in other industries

1. [MFA Financial, Inc.](https://www.sectoralpha.in/us/stocks/mfa) $685 million · REIT - Mortgage
2. [Fox Factory Holding Corp.](https://www.sectoralpha.in/us/stocks/foxf) $683 million · Auto Parts
3. Mesa Laboratories, Inc. $683 million
4. [Bally's Corporation](https://www.sectoralpha.in/us/stocks/baly) $682 million · Resorts & Casinos
5. [ACNB Corporation](https://www.sectoralpha.in/us/stocks/acnb) $682 million · Banks - Regional

## What else do people ask about Mesa Laboratories? ### What were Mesa Laboratories's latest quarterly results? Mesa Laboratories, Inc. reported revenue of $60.1 M and net profit of $2.8 M for the Jun 2026 quarter. Revenue rose 1.0% and profit fell 40.3% compared with a year earlier. Earnings per share were $0.49. The operating margin was 11.7%, 6.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Mesa Laboratories's market cap? Mesa Laboratories, Inc.'s market capitalisation is $702 M at a stock price of $125.48. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Mesa Laboratories performing? Mesa Laboratories, Inc.'s share price has been rising for 15 weeks. In its latest quarter, revenue rose 1.0% and profit fell 40.3% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running (as of 3 November 2026). ### Will Mesa Laboratories's stock price go up? This page does not forecast Mesa Laboratories, Inc.'s stock price. What it shows instead: the stock price is $125.48, and it has been rising for 15 weeks. Its P/E of 145.8× is higher than 23% of its own last 5 years (as of 3 November 2026). ### Is Mesa Laboratories's profit real cash? Yes, over the last 3 years, 1,157% of Mesa Laboratories, Inc.'s reported profit came in as cash from operations. The latest year was lower at 638%, so the trend is worth watching. In FY26, operating cash was $42.8 M against reported profit of $6.7 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 3 November 2026). ### Where is Mesa Laboratories in its business cycle? Mesa Laboratories, Inc.'s FY26 operating margin was 7.4%, against a 5-year range of 1.5% to 7.4%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 11.7%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Mesa Laboratories story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Mesa Laboratories a stock worth studying right now? What the numbers show: Mesa Laboratories, Inc.'s results are improving, while its P/E is near the low end of its own history over 4.6 years, higher than only 23% of past readings. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ## Lists

- US tech stocks: https://www.sectoralpha.in/us-tech-stocks

This is research, not advice. We’re not SEBI-registered.